Recent Developments in the Treatment and Management of Psoriatic Arthritis

A continuing medical education activity sponsored by NAMCP and AAMCN.

This activity is an archive from the live session from the 2020 Spring Managed Care Forum. If you participated in the live session, you are not eligible for continuing education credits from this archive

This activity is valid from June 1, 2020 to June 1, 2021

Instructions for CME/NCPD: Complete the pre-test, listen to the audio and view the slides, complete the post test, complete the evaluation form and hit submit. You will be asked to enter your name and email address on the pre-test, evaluation, and post-test. If you close your internet browser without completing the post test, you will have ONE more opportunity to complete. A score of 70% must be achieved on the post-test to receive continuing education credits. If you do not pass the post-test after two attempts, you will not be eligible to try again. Once you complete the evaluation form and score 70% or higher on your post-test, you will automatically be given your certificate.

To print or save your certificate, you will need to click on the “download” button and either print or save.

 

Audience: This activity is intended for healthcare professionals practicing in managed care environments.

This presentation is supported by an educational grant from
Novartis Pharmaceuticals Corporation

Description:
Psoriatic arthritis is a progressive, inflammatory disease that is associated with a number of dermatologic and musculoskeletal manifestations. Patients can experience extreme pain and joint damage that may affect their quality of life, physical function, and ability to work. Symptoms include fatigue, joint inflammation, and potentially progressive joint damage. Diagnosing psoriatic arthritis can be very complex with the most critical factor being the absence of validated criteria for identifying and classifying cases that will help diagnose the disease. The standard diagnostic measures are based on history, a physical exam and x-ray features, so establishing the presence of characteristic signs and symptoms associated in both the skin and joints, and by ruling out more common inflammatory arthritis, can be very helpful. The diagnosis of psoriatic arthritis can sometimes be delayed or missed by primary care providers and other healthcare professionals. The past few years have seen a number of treatments introduced for psoriatic arthritis. Along with symptomatic treatments, such as nonsteroidal anti-inflammatory drugs (NSAIDs), corticosteroids, and local corticosteroid injections into joints, there are also the oral small molecules (OSMs) for treatment. The Tumor Necrosis Factor (TNF) inhibitors have been available for nearly 20 years and continue to be a viable option for patients. More recently key cytokines in the psoriatic disease pathophysiology have been introduced and they include Janus kinases and signal transducers and activators of transcription (JAK-STATs) as well as are the interleukin (IL)-12, IL-17, IL-22 and IL-23 pathway inhibitors. These newer biologic treatments target some of these key cytokines to treat psoriatic disease.

Upon completion of this activity, participants will be able to:

  • Identify treatment strategies explaining psoriatic arthritis (PsA) pathophysiology and mechanisms of action of targeted therapies for PsA

  • Assess different strategies to evaluate PsA severity that incorporate both joint and skin manifestation in order to guide appropriate management plans

  • Explore clinical evidence of effectiveness and safety of targeted biologic and small-molecule therapies to guide treatment decisions for patients with PsA

  • Identify individualized management plans for newly diagnosed patients with PsA, including the long-term treatment impact of current biologics

  • Evaluate multidisciplinary care team strategies to overcome different challenges in PsA management

     

Faculty: Allan Gibofsky, MD, JD
Professor of Medicine, Healthcare Policy and Research
Weill Medical College of Cornell University
Attending Rheumatologist
Hospital for Special Surgery

Disclosure:

Dr. Gibofsky serves on an advisory board and is a consultant for AbbVie, Gilead, Lilly, Novartis, and Pfizer. He serves on the speaker's bureau for AbbVie, Lilly, Novartis, and Pfizer. He owns and self-manages stock in AbbVie, BMS, Lilly, and Pfizer. His presentation has been peer reviewed for any bias.
  Planning Committee:
Bill Williams, MD has no relevant financial relationships to disclose.
Jeremy Williams has no relevant financial relationships to disclose.
Will Williams has no relevant financial relationships to disclose.
Jacqueline Cole, RN, MS, CMCN has no relevant financial relationships to disclose.

NAMCP and/or the presenter has copyright or has received permissions for use of materials provided in this activity.

Accreditation & Designation
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the National Association of Managed Care Physicians (NAMCP) and American Association of Managed Care Nurses (AAMCN). The National Association of Managed Care Physicians is accredited by the ACCME to provide continuing medical education for physicians.

NAMCP designates this enduring material for a maximum of 1 AMA PRA Category 1 credit(s)TM. Each
physician should claim credit commensurate with the extent of their participation in the activity.

The American Association of Managed Care Nurses is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation.

Nurses who complete this activity and achieve a passing score will receive 1 hour in nursing continuing professional development.

This activity has been approved by the American Board of Managed Care Nursing for 1.0 contact hours toward CMCN recertification requirements.

This presentation is supported by an educational grant from
Novartis Pharmaceuticals Corporation

NAMCP and/or this website does not provide medical advice, diagnosis or treatment. NAMCP does not endorse or imply endorsement of the content on any linked website. This website is to be used as an informational resource. With any health related concern, consult with your physician or healthcare professional.

Click Here To Continue